A Phase 1 clinical trial evaluating survodutide has reached completed status as of August 4, 2026. The study, registered as NCT07221591, was titled "A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body." This trial focused on comparing how two different formulations of survodutide are absorbed by the body in healthy participants.
Survodutide remains an unapproved compound classified as a research substance. It has not received regulatory approval for clinical use. This trial update reflects only the completion status of the study as recorded, and no results or outcome data have been disclosed as part of this update.
The study is documented on ClinicalTrials.gov under the identifier NCT07221591. The trial was categorized as Phase 1, the initial stage of human clinical testing typically focused on safety and pharmacokinetic properties such as absorption. No efficacy or safety conclusions can be drawn from a completion status alone.
Further details regarding the trial design, methodology, and any eventual results would need to be obtained through official channels or subsequent publications. For additional context on survodutide as a compound, readers can consult the compound overview.